Compare AKTX & JXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKTX | JXG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 7.5M |
| IPO Year | 2014 | N/A |
| Metric | AKTX | JXG |
|---|---|---|
| Price | $0.23 | $3.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.53 | N/A |
| AVG Volume (30 Days) | ★ 183.7K | 3.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.23 |
| 52 Week High | $1.72 | $10.29 |
| Indicator | AKTX | JXG |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 49.19 |
| Support Level | $0.22 | $3.70 |
| Resistance Level | $0.27 | $4.39 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 6.32 | 65.47 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.